Vernakalant hydrochloride to treat atrial fibrillation

Bibliography

• Camm J, Lip GYH, DeCaterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012;33:2719-47
   PubMed Web of Science ®Google Scholar
• Heijman J, Voigt N, Dobrev D. New directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiol 2013;9:71-88
   PubMedGoogle Scholar
• Veenhuyzen GD, Simpson CS, Abdollah H. Atrial fibrillation. Cmaj 2004;171:755-60
   PubMedGoogle Scholar
• Hayward CS, Kraidly M, Webb CM, Collins P. Assessment of endothelial function using peripheral waveform analysis: a clinical application. J Am Coll Cardiol 2002;40:521-8
   PubMedGoogle Scholar
• Comtois P, Kneller J, Nattel S. Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry. Europace 2005;7:10-20
   PubMed Web of Science ®Google Scholar
• Nattel S, Dobrev D. The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J 2012;33:1870-7
   PubMed Web of Science ®Google Scholar
• Camm J, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429
   PubMed Web of Science ®Google Scholar
• Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP, et al.; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33
   PubMed Web of Science ®Google Scholar
• Carlsson J, Miketic S, Windeler J, et al.; STAF Investigators. Randomized trial of rate-control versus rhythm control in persistent atrial fibrillation. J Am Coll Cardiol 2003;41:1690-6
   PubMed Web of Science ®Google Scholar
• de Denus S, Sanoski CA, Carlsson J, et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005;165:258-62
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Burashnikov A. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. J Electrocardiol 2009;42:543-8
   PubMed Web of Science ®Google Scholar
• Lee W, Ryu DR, Han SS, et al. Very early onset of amiodarone-induced pulmonary toxicity. Korean Circ J 2013;43:699-701
   PubMedGoogle Scholar
• Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76
   PubMed Web of Science ®Google Scholar
• Felser A, Blum K, Lindinger PW, et al. Mechanisms of hepatocellular toxicity associated with dronedarone – a comparison to amiodarone. Toxicol Sci 2013;131:480-90
   PubMed Web of Science ®Google Scholar
• Allison B, Yang Y, Pourrier M, Gibson JK. Comparison of the in vivo hemodynamic effects of the antiarrhythmic agents vernakalant and flecainide in a rat hindlimb perfusion model. J Cardiovasc Pharmacol 2011;57:463-8
   PubMedGoogle Scholar
• Fedida D, Orth PMR, Chen JYC, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005;16:1227-38
   PubMed Web of Science ®Google Scholar
• Dorian P, Pinter A, Mangat I, et al. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007;50:35-40
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Dobrev D. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update. Vasc Health Risk Manag 2013;9:165-75
   PubMedGoogle Scholar
• Roy D, Rowe BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-61
   PubMed Web of Science ®Google Scholar
• Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-25
   PubMed Web of Science ®Google Scholar
• Pratt CM, Roy D, Torp-Pedersen C, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol 2010;106:1277-83
   PubMed Web of Science ®Google Scholar
• Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:652-9
   PubMed Web of Science ®Google Scholar
• Orth PMR, Hesketh JC, Mak CKH, et al. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res 2006;70:486-96
   PubMed Web of Science ®Google Scholar
• Varkevisser R, Van der Heyden MA, Tieland RG, et al. Vernakalant is devoid of proarrhythmic effects in the complete AV block dog model. Eur J Pharmacol 2013;720:49-54
   PubMedGoogle Scholar
• Mao ZL, Wheeler JJ, Clohs L, et al. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol 2009;49:17-29
   PubMed Web of Science ®Google Scholar
• Mao Z, Wheeler JJ, Townsend R, et al. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter. J Pharmacokinet Pharmacodyn 2011;38:541-62
   PubMedGoogle Scholar
• Mao ZL, Alak A, Wheeler JJ, Keirns J. Disposition and mass balance of [14C]vernakalant after single intravenous and oral doses in healthy volunteers. Drug Metab Lett 2011;5:114-25
   PubMedGoogle Scholar
• Mao ZL, Townsend RW, Gao Y, et al. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter. J Clin Pharmacol 2012;52:1042-53
   PubMedGoogle Scholar
• Stiell IG, Roos JS, Kavanagh KM, Dickinson G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J 2010;159:1095-101
   PubMed Web of Science ®Google Scholar
• Camm AJ, Toft E, Torp-Pedersen C, et al. Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial. Europace 2012;14:804-9
   PubMed Web of Science ®Google Scholar
• He Y, Thi Thi A, Zhong G, et al. Meta-analysis of effect of vernakalant on conversion of atrial fibrillation. BMC Res Notes 2013;6:94
   PubMedGoogle Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12
   PubMedGoogle Scholar
• European Medicines Agency (EMA) Assessment Report for Brinavess. EMA 2010. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001215/WC500097150.pdf [Last accessed 6 March 2014]
   Google Scholar
• Camm AJ, Capucci A, Hohnloser SH, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57:313-21
   PubMed Web of Science ®Google Scholar
• Chow MS. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Ann Pharmacother 1996;30:637-43
   PubMed Web of Science ®Google Scholar
• Savelieva I, Graydon R, Camm AJ. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. Europace 2014;16(2):162-73
   PubMedGoogle Scholar
• de Riva-Silva M, Montero-Cabezas JM, Salgado-Aranda R, et al. 1:1 atrial flutter after vernakalant administration for atrial fibrillation cardioversion. Rev Esp Cardiol (Engl Ed) 2012;65:1062-4
   PubMedGoogle Scholar
• Franzini C, Muller-Burri SA, Shah DC. Atrial flutter with 1 : 1 atrioventricular conduction after administration of vernakalant for atrial fibrillation. Europace 2014;16:3
   PubMedGoogle Scholar
• Bash LD, Buono JL, Davies GM, et al. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther 2012;26:167-79
   PubMedGoogle Scholar
• Conde D, Costabel JP, Caro M, et al. Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. Int J Cardiol 2013;168:2423-5
   PubMed Web of Science ®Google Scholar
• Conde D, Costabel JP, Aragon M, et al. Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation. Cardiovasc Ther 2013;31:377-80
   PubMedGoogle Scholar
• Crijns HJ. Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation. Maastricht University Medical Center 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01646281 [Last accessed 6 March 2014]
   Google Scholar
• van Middendorp LB, Strik M, Houthuizen P, et al. Electrophysiological and haemodynamic effects of vernakalant and flecainide in dyssynchronous canine hearts. Europace 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Koskinas KC, Fragakis N, Katritsis D, et al. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Hernandez-Madrid A, Svendsen JH, Lip GY, et al. Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey. Europace 2013;15:915-18
   PubMed Web of Science ®Google Scholar
• Dobrev D, Hamad B, Kirkpatrick P. Vernakalant. Nat Rev Drug Discov 2010;9:915-16
   PubMed Web of Science ®Google Scholar